First patient trial will test new approach to treating Alzheimer’s disease

UCL | October 2018 | First patient trial will test new approach to treating Alzheimer’s disease

A new clinical trial that is using a novel approach to the progression of Alzheimer’s disease is being led by UCL researchers in London. The trial known as DESPIAD will study whether a drug that removes a protein from the brain can help patients with Alzheimer’s disease. 


 “After a long struggle for funding of our different approach to possible treatment of Alzheimer’s disease, it is exciting to finally have started the DESPIAD trial, which has been made possible by the NIHR and the Wolfson Foundation. We now hope it can proceed as swiftly as possible,” said Professor Sir Mark Pepys (UCL Medicine), who led the development of the new drug.

Almost all medications tested have been focussed on the abnormal fibrous protein accumulations, known as amyloid plaques and neurofibrillary tangles, which are always present in the brain in Alzheimer’s disease. The drugs have aimed at removing or preventing the formation of these abnormal deposits (Source: UCL).

For the full details of the trial, read the press release from  UCL 

See also:

NIHR | Landmark new trial starts for novel Alzheimer’s disease treatment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s